Gustavo A. Rosario Benitez

Array ( [id] => 9964254 [patent_doc_number] => 09011860 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-04-21 [patent_title] => 'Compositions for inhibiting MASP-2 dependent complement activation' [patent_app_type] => utility [patent_app_number] => 13/464334 [patent_app_country] => US [patent_app_date] => 2012-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 38 [patent_no_of_words] => 43983 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13464334 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14594131 [patent_doc_number] => 10350242 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-16 [patent_title] => Methods for handling biological drugs containing living cells [patent_app_type] => utility [patent_app_number] => 13/581895 [patent_app_country] => US [patent_app_date] => 2012-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 54 [patent_no_of_words] => 8618 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 170 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13581895 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8503057 [patent_doc_number] => 20120302466 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-11-29 [patent_title] => 'T CELL RECEPTOR-DEFICIENT T CELL COMPOSITIONS' [patent_app_type] => utility [patent_app_number] => 13/459664 [patent_app_country] => US [patent_app_date] => 2012-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 17841 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13459664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9970674 [patent_doc_number] => 09017679 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-04-28 [patent_title] => 'Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins' [patent_app_type] => utility [patent_app_number] => 13/457583 [patent_app_country] => US [patent_app_date] => 2012-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 53 [patent_no_of_words] => 22236 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13457583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8994525 [patent_doc_number] => 08518407 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-08-27 [patent_title] => 'Therapeutic human anti-IL-1R1 monoclonal antibody' [patent_app_type] => utility [patent_app_number] => 13/450126 [patent_app_country] => US [patent_app_date] => 2012-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 37 [patent_no_of_words] => 33574 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13450126 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9434976 [patent_doc_number] => 20140112883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-24 [patent_title] => 'METHODS FOR REDUCING AN ADVERSE IMMUNE RESPONSE TO A FOREIGN ANTIGEN IN A HUMAN SUBJECT WITH ANTI-CD4 ANTIBODIES OR CD4-BINDING FRAGMENTS THEREOF OR CD4-BINDING MOLECULES' [patent_app_type] => utility [patent_app_number] => 14/112745 [patent_app_country] => US [patent_app_date] => 2012-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 17532 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 24 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14112745 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8977619 [patent_doc_number] => 20130211049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-15 [patent_title] => 'IMMUNOTOXIN FUSION PROTEINS AND MEANS FOR EXPRESSION THEREOF' [patent_app_type] => utility [patent_app_number] => 13/443779 [patent_app_country] => US [patent_app_date] => 2012-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 58 [patent_no_of_words] => 57859 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13443779 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9849795 [patent_doc_number] => 08951522 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-02-10 [patent_title] => 'Methods for treating conditions associated with MASP-2 dependent complement activation' [patent_app_type] => utility [patent_app_number] => 13/441827 [patent_app_country] => US [patent_app_date] => 2012-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 63 [patent_no_of_words] => 80534 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13441827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8289855 [patent_doc_number] => 20120178184 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-12 [patent_title] => 'T CELL PROTEINS AND NUCLEOTIDES ENCODING THE SAME' [patent_app_type] => utility [patent_app_number] => 13/433444 [patent_app_country] => US [patent_app_date] => 2012-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 8488 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13433444 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8611856 [patent_doc_number] => 20130017168 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-17 [patent_title] => 'METHODS FOR ENHANCING THE EFFICACY OF IL-2 MEDIATED IMMUNE RESPONSES' [patent_app_type] => utility [patent_app_number] => 13/434354 [patent_app_country] => US [patent_app_date] => 2012-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 22290 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13434354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8820967 [patent_doc_number] => 20130122011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-05-16 [patent_title] => 'Multiple-variable dose regimen for treating TNFa-related disorders' [patent_app_type] => utility [patent_app_number] => 13/433205 [patent_app_country] => US [patent_app_date] => 2012-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 48032 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13433205 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11561720 [patent_doc_number] => 09624292 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-18 [patent_title] => 'Single chain antigen recognizing constructs (scARCs) stabilized by the introduction of novel disulfide bonds' [patent_app_type] => utility [patent_app_number] => 14/006254 [patent_app_country] => US [patent_app_date] => 2012-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 10 [patent_no_of_words] => 10346 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 215 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14006254 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8441424 [patent_doc_number] => 20120258040 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-10-11 [patent_title] => 'COMPOSITIONS AND METHODS OF MONOCLONAL AND POLYCLONAL ANTIBODIES SPECIFIC FOR T CELL SUBPOPULATIONS' [patent_app_type] => utility [patent_app_number] => 13/423683 [patent_app_country] => US [patent_app_date] => 2012-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 29605 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13423683 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9490611 [patent_doc_number] => 20140141016 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-05-22 [patent_title] => 'ANTIBODIES TO CD70' [patent_app_type] => utility [patent_app_number] => 14/005113 [patent_app_country] => US [patent_app_date] => 2012-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 45811 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14005113 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8416664 [patent_doc_number] => 20120244162 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-09-27 [patent_title] => 'CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS' [patent_app_type] => utility [patent_app_number] => 13/408363 [patent_app_country] => US [patent_app_date] => 2012-02-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 51379 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13408363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8323955 [patent_doc_number] => 20120196361 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-02 [patent_title] => 'MART-1 T CELL RECEPTORS' [patent_app_type] => utility [patent_app_number] => 13/399922 [patent_app_country] => US [patent_app_date] => 2012-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 26027 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13399922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8323955 [patent_doc_number] => 20120196361 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-02 [patent_title] => 'MART-1 T CELL RECEPTORS' [patent_app_type] => utility [patent_app_number] => 13/399922 [patent_app_country] => US [patent_app_date] => 2012-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 26027 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13399922 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9074213 [patent_doc_number] => 08551790 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-10-08 [patent_title] => 'MASP 2, a complement-fixing enzyme, and uses for it' [patent_app_type] => utility [patent_app_number] => 13/359348 [patent_app_country] => US [patent_app_date] => 2012-01-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 8 [patent_no_of_words] => 16222 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13359348 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8184139 [patent_doc_number] => 20120114651 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-10 [patent_title] => 'METHODS FOR TARGETING PULMONARY DISEASES WITH AGENTS THAT BIND A TARGET IN PULMONARY TISSUE' [patent_app_type] => utility [patent_app_number] => 13/356228 [patent_app_country] => US [patent_app_date] => 2012-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 87 [patent_figures_cnt] => 87 [patent_no_of_words] => 47870 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13356228 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8312598 [patent_doc_number] => 20120189621 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-26 [patent_title] => 'Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists' [patent_app_type] => utility [patent_app_number] => 13/354813 [patent_app_country] => US [patent_app_date] => 2012-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 17312 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13354813 [rel_patent_id] =>[rel_patent_doc_number] =>)